Recently announced outcomes-based contracts for drugs marketed by Amgen Inc. and Novartis AG have garnered much publicity but their primary near-term benefit will be the development of systems for collecting and evaluating data to prove outcomes, predicts pharmacy benefit manager Express Scripts Holding Co. Chief Medical Officer Steve Miller.
The contracts will probably not do much to lower drug costs initially but they will make important progress toward that...